Prostaglandin E₂ and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells

Y Chen and M Hughes-Fulford

Laboratory of Cell Growth, University of California, San Francisco and Veterans Affairs Medical Center, Mail Code 151F, 4150 Clement Street, San Francisco, CA 94121, USA

Summary Arachidonic acid (AA) is the precursor for prostaglandin E₂ (PGE₂) synthesis and increases growth of prostate cancer cells. To further elucidate the mechanisms involved in AA-induced prostate cell growth, induction of c-fos expression by AA was investigated in a human prostate cancer cell line, PC-3. c-fos mRNA was induced shortly after addition of AA, along with a remarkable increase in PGE₂ production. c-fos expression and PGE₂ production induced by AA was blocked by a cyclo-oxygenase inhibitor, flurbiprofen, suggesting that PGE₂ mediated c-fos induction. Protein kinase A (PKA) inhibitor H-89 abolished induction of c-fos expression by AA, and partially inhibited PGE₂ production. Protein kinase C (PKC) inhibitor GF109203X had no significant effect on c-fos expression or PGE₂ production. Expression of prostaglandin (EP) receptors, which mediate signal transduction from PGE₂ to the cells, was examined by reverse transcription polymerase chain reaction in several human prostate cell lines. EP4 and EP2, which are coupled to the PKA signalling pathway, were expressed in all cells tested. Expression of EP1, which activates the PKC pathway, was not detected. The current study showed that induction of the immediate early gene c-fos by AA is mediated by PGE₂, which activates the PKA pathway via the EP2/4 receptor in the PC-3 cells. © 2000 Cancer Research Campaign

Keywords: prostate cancer; c-fos; arachidonic acid; prostaglandin E₂; protein kinase; gene expression; prostaglandin receptor; EP4

Dietary fatty acid intake is associated with the risk of development and progression of prostate, colon and breast cancer (Marnett, 1992; Rose, 1997). In vitro and in vivo studies suggest that the availability of polyunsaturated fatty acids contributes to increased cancer cell growth, and that inhibitors of the eicosanoids synthesis pathway inhibit cell proliferation (Rose and Connolly, 1991; Connolly et al, 1997).

Arachidonic acid (AA) is derived from the essential polyunsaturated fatty acid, linoleic acid, which is commonly available in dietary fat. It is the major precursor of biologically active eicosanoids, which include prostaglandins, thromboxanes and leukotrienes. Among these is prostaglandin E₁ (PGE₁), a product catalysed by the key enzyme cyclo-oxygenase (COX, EC 1.14.99.1). Two isoforms of COX exist in human prostate cells. COX-1 is a constitutively expressed enzyme, whereas COX-2 is inducible. O’Neill and Ford-Hutchinson (1993) have reported that the human prostate cells express similar amounts of COX-1 and COX-2. In human prostate tissues, PGE₁ is the only significant eicosanoid produced (Chaudry et al, 1994). PGE₁ induces a variety of cell responses depending on the tissue type and the receptors involved, such as immune regulation (Monick et al, 1987; Juzan et al, 1992; Marnett, 1992), smooth muscle contraction (Coleman and Kennedy, 1985) and regulation of water re-adsorption in kidney (Smith, 1989). Previous studies with osteoblasts and prostate cancer cells have demonstrated that PGE₁ stimulates cell growth (Raisz et al, 1993; Tjandrawinata et al, 1997).

Studies from this laboratory indicate that AA stimulates growth of a prostate cell line, PC-3 (manuscript submitted). Because of the role of PGE₂ in prostate cancer cell growth, we hypothesized that AA had the stimulatory effect on the prostate cancer cells through the activity of its metabolite PGE₂, and aimed to understand the signal transduction events following AA administration which lead to the growth of the cells. After being synthesized and exported out of the cells, PGE₂ exerts its functions by interacting with the PGE₂ receptors (EPs), which are 7-domain transmembrane cell surface receptors. Four subtypes of EP receptors have been identified and characterized. These receptors are coupled to G proteins, and activate or inhibit second messenger systems inside the cell. EP1 causes influx of Ca²⁺ and activation of protein kinase C (PKC); receptors EP2 and EP4 activate the adenylate cyclase which increases cellular cyclic AMP level and activates protein kinase A (PKA); EP3 signals primarily through an inhibitory G protein to decrease intracellular cyclic AMP levels (Negishi et al, 1995).

Despite the important association of AA and PGE₂ with prostate cancer, the signals mediating the biological functions of these molecules in prostate cancer cells are not fully understood. The signalling pathways mediating AA- or PGE₂-induced cell growth or expression of growth-related proto-oncogenes have been investigated in a number of studies with varying conclusions. In bone cells, a PKA-mediated mechanism has been suggested (Fitzgerald et al, 1999; Weinreb et al, 1999). A study of smooth muscle cells demonstrated a role for PKC as a mediator of AA-induced c-fos
expression (Rao et al, 1993). In the Swiss 3T3 fibroblast cells, however, there are conflicting data on whether PKC or PKA is involved (Kacich et al, 1988; Mehmet et al, 1990; Danesch et al, 1994). Our results indicate that the PKA-dependent pathway via the EP4 receptor is responsible for mediating AA-induced c-fos expression in human prostate cancer cells.

**MATERIALS AND METHODS**

**Materials**
AA, flurbiprofen, and 12-O-tetradecanoylphorbol 13-ace-tate (TPA) were purchased from Sigma (St Louis, MO, USA). PKC inhibitor GF109203X and PKA inhibitor H-89 were from BIOMOL (Plymouth Meeting, PA, USA). PGE2 was from Oxford (Oxford, MI, USA). RPMI-1640 medium, l-glutamine, and antibiotics were from UCSF Cell Facility (San Francisco, CA, USA). Fetal calf serum (FCS) was purchased from Hyclone Laboratories (Logan, UT, USA).

**Cell culture**
The PC-3, DU145 and LNCaP human prostate cancer cell lines were cultured in complete RPMI-1640 medium supplemented with 10% FCS, 2 mM l-glutamine, 25 mM glucose, 1 mM pyruvic acid, 100 units ml−1 penicillin, 100 µg ml−1 streptomycin and 0.25 µg ml−1 amphotericin B. The PrEC normal human prostate epithelial cells (Clonetics, San Diego, CA, USA) were maintained in the PrEGM medium (Clonetics). All cells were cultured with 5% carbon dioxide at 37°C. For c-fos expression experiments, cells were grown in complete RPMI medium with 5% FCS for 2 days, and then 1% FCS for 24 h before cells were harvested for RNA isolation.

**PCR primers**
Specific polymerase chain reaction (PCR) primers (see Table 1) were designed by MHF. The primer pairs span introns of the genes, so that the reverse transcription PCR (RT-PCR) products may be distinguished from any possible PCR products resulted from contaminating genomic DNA. Primers were synthesized by Operon Technologies (Alameda, CA, USA).

**Semi-quantitative RT-PCR**
Semi-quantitative kinetic RT-PCR was used for analysis since this is the most versatile and inexpensive method available. The PCR efficiency of the reactions was checked by examining the slopes of the PCR product curves and internal standards of housekeeping genes from the same samples. RNA was isolated from cells grown in 6-well plates using the TRIReagent (Sigma) as recommended by the company. RNA was quantified in the GeneQuant spectrophotometer (Pharmacia, Piscataway, NJ, USA). The RNA PCR kit from PE Applied Biosystems (Foster City, CA, USA) was used for reverse transcription and PCR following procedures recommended by the manufacturer. An aliquot of 1.5 µg RNA was reverse transcribed in 30 µl of buffer. Five microlitres of the reverse transcription reaction was PCR-amplified using specific primers. A temperature cycle in PCR was 94°C for 1 min 40 s, 63°C for 1 min 10 s and 72°C for 1 min 40 s. PCR was carried out in a Robocycler 40 (Stratagene, San Diego, CA, USA) for various cycle numbers depending on the primers used (the cycle numbers are described in the legends for Tables and Figures). PCR cycle numbers were maintained within a linear amplification range. The PCR products were separated by electrophoresis in 2% agarose gels. The gels were photographed and DNA bands of interest were scanned at 400 dpi with an Epson Perfection 636 scanner. Areas and densities of the DNA bands were determined using the SigmaGel software (Sigma).

**PGE2 assay**
An aliquot of culture medium was collected and frozen at −70°C before the cells were harvested for RNA isolation. PGE2 levels in the culture medium samples were determined using a PGE2 monoclonal enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA), following the protocols recommended by the company. A Dynatech MR5000 microplate reader (Dynatech Laboratories, Chantilly, VA, USA) was used to read the assay results. Data were analysed using the BioLinx 2.0 software (Dynatech).

**Statistical analysis**
For each treatment in the experiments, three independent samples were seeded, treated and their RNA or media samples analysed separately. Mean and standard deviation (s.d.) of the three samples

---

**Table 1** Primers used in RT-PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Orientation</th>
<th>Sequence</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>c-fos</td>
<td>Sense</td>
<td>5′-GAATAAGATGGCGCTGCAGCCAAATGCCGCAA-3′</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>Anti-sense</td>
<td>5′-CAGTCAGATCAAGGGAAGCCACAGACATCT-3′</td>
<td></td>
</tr>
<tr>
<td>Cyclophilin</td>
<td>Sense</td>
<td>5′-CGTCTCCTTGTAGCTTGTGCGAC-3′</td>
<td>628</td>
</tr>
<tr>
<td></td>
<td>Anti-Sense</td>
<td>5′-CATAACTCAAACTTAACTTCGCAATACTCCACG-3′</td>
<td></td>
</tr>
<tr>
<td>EP1</td>
<td>Sense</td>
<td>5′-CCACCCACCTCTCTGCTGTCTGG-3′</td>
<td>1037</td>
</tr>
<tr>
<td></td>
<td>Anti-sense</td>
<td>5′-GGTTGCGGCTGTTCTAGTGTTG-3′</td>
<td></td>
</tr>
<tr>
<td>EP2</td>
<td>Sense</td>
<td>5′-CCTGTGGGCACTTTGTTGTGT-3′</td>
<td>784</td>
</tr>
<tr>
<td></td>
<td>Anti-sense</td>
<td>5′-GGGCTCTAGATGGGGTTTAC-3′</td>
<td></td>
</tr>
<tr>
<td>EP3</td>
<td>Sense</td>
<td>5′-CGCCTCAACACCTCTACTAACA-3′</td>
<td>837</td>
</tr>
<tr>
<td></td>
<td>Anti-sense</td>
<td>5′-CCAGACCGAACACAGACACCACAT-3′</td>
<td></td>
</tr>
<tr>
<td>EP4</td>
<td>Sense</td>
<td>5′-AGGTTGCTTCTGCTGTTGCTCG-3′</td>
<td>344</td>
</tr>
</tbody>
</table>

© 2000 Cancer Research Campaign  
RESULTS

AA transiently increases c-fos mRNA expression in PC-3 cells

A previous study from this laboratory demonstrated that AA induces c-fos expression in the PC-3 human prostate cancer cells (manuscript submitted). In this study, AA was added to the PC-3 cells at a concentration of 1 µg ml⁻¹ since previous work demonstrated that c-fos expression can be up-regulated with as low as 0.1 µg ml⁻¹ of AA, and that the effect is near maximum when the AA concentration is at 0.5 µg ml⁻¹. Fifteen, 30, 60 and 180 min after addition of AA, total RNA was isolated from the cells and was subjected to RT-PCR analysis to observe level of c-fos mRNA. Table 2 summarizes the relative level of c-fos product after being normalized to the internal control, cyclophilin. c-fos message was induced as early as 15 min after AA addition to cell culture, and was greater than 1.9-fold higher than the non-treated control at 1 h. Three hours after AA addition, c-fos mRNA level began to decrease, suggesting that c-fos induction was transient and was regulated by other downstream events. Based on these observations, cells and medium samples were collected 1 h after AA was added to culture media for all subsequent AA-induction experiments.

AA-induced c-fos expression is mediated by PGE₂

Because AA is the precursor of PGE₂, it was speculated that the AA-induced c-fos expression was due to increased PGE₂ production by the PC-3 cells. Culture medium samples collected from the experiment presented in Table 2 were analysed for their PGE₂ levels. As expected, PGE₂ production of the PC-3 cells increased shortly after its precursor, AA, became available to the cells and PGE₂ level remained elevated for at least 3 h (Table 2).

In order to confirm that PGE₂ mediated AA-induced c-fos expression, we blocked PGE₂ synthesis with a non-steroidal anti-inflammatory drug (NSAID). Flurbiprofen, which suppresses cyclo-oxygenases and subsequently PGE₂ production, was added to the cells before the AA treatment. As shown in Figure 1A, c-fos message induction by AA was statistically significant (P = 0.004) in absence of flurbiprofen, but was not significant (P = 0.840) in presence of flurbiprofen. (B) PGE₂ (4 µg ml⁻¹) was added to the cells 30 min before harvest. Induction by PGE₂ was significant (P = 0.009).

Table 2  AA-induced c-fos mRNA expression and PGE₂ production in PC-3 cells

<table>
<thead>
<tr>
<th>Incubation time with AA</th>
<th>Relative c-fos product</th>
<th>PGE₂ concentration (µg ml⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>2.81 ± 0.26</td>
<td>80 ± 34</td>
</tr>
<tr>
<td>15 min</td>
<td>3.59 ± 1.09</td>
<td>361 ± 107</td>
</tr>
<tr>
<td>30 min</td>
<td>4.42 ± 0.47</td>
<td>402 ± 18</td>
</tr>
<tr>
<td>1 h</td>
<td>5.46 ± 0.53</td>
<td>426 ± 52</td>
</tr>
<tr>
<td>3 h</td>
<td>3.62 ± 0.69</td>
<td>558 ± 131</td>
</tr>
</tbody>
</table>

Total RNA was isolated from the PC-3 cells after incubation with AA (1 µg ml⁻¹) for a time period indicated in the Table. RT-PCR with c-fos and cyclophilin primers was performed on the RNA samples. PCR reactions with c-fos and cyclophilin primers had 29 and 19 temperature cycles respectively. The amount of c-fos RT-PCR product was normalized to that of cyclophilin product. Mean ± s.d. of three independent samples is shown in this bar graph. Ctrl = control; Flub = flurbiprofen.

Figure 1  Effect of NSAID and PGE₂ on AA-induced c-fos expression in PC-3 cells. Cells were treated as indicated before harvested for total RNA isolation and subsequent RT-PCR. Amount of c-fos RT-PCR product was normalized to that of cyclophilin product. Mean ± s.d. of three independent samples is shown in this bar graph. Ctrl = control; Flub = flurbiprofen. (A) Flurbiprofen (30 µM) was added to the cells 3 h before harvest and AA (1 µg ml⁻¹) was added 1 h before harvest. c-fos induction by AA was statistically significant (P = 0.004) in absence of flurbiprofen, but was not significant (P = 0.840) in presence of flurbiprofen. (B) PGE₂ (4 µg ml⁻¹) was added to the cells 30 min before harvest. Induction by PGE₂ was significant (P = 0.009).

AA-induced c-fos expression is dependent on the PKA signalling pathway

The EP receptors for PGE₂ are coupled to either PKC or PKA pathways. To determine which EP receptor signalling pathway is


© 2000 Cancer Research Campaign
involved in the AA-induced c-fos expression in the PC-3 cells, specific protein kinase inhibitors were used to treat the cells before AA was added. Treatment with H-89, a selective inhibitor of PKA (Chijiwa et al, 1990), resulted in loss of c-fos induction by AA (Figure 3). Inhibition of PKA also lowered PGE2 production by 2.8-fold after AA was added to the cells (Figure 4).
PGE₂ level, however, was still 4.6-fold higher than the control samples, or 3.7-fold higher than the samples treated with H-89 but not with AA.

The specific PKC inhibitor, GF109203X (Toullec et al, 1991), was added to the cells prior to AA treatment in order to determine whether PKC is involved in c-fos induction in PC-3 cells. Figure 5A shows that inhibition of PKC did not significantly block AA-induced c-fos expression. The inhibitory effect of GF109203X was demonstrated by its strong inhibition of c-fos expression induced by TPA, which is a potent activator of PKC (Figure 5B). AA-induced PGE₂ production in PC-3 cells was also not affected by treatment with GF109203X (Figure 6).

Taken together, the results suggest that the PKA but not PKC signalling pathway is responsible for PGE₂ signal transduction that leads to increased c-fos expression after addition of AA. Therefore, the EP1 receptor, which activates the PKC pathway, is not likely to be involved in receiving the PGE₂ signal in PC-3 cells.

**Human prostate cells express the prostaglandin receptors EP4 and EP2**

Expression of different EP receptors was examined in three human prostate cancer cell lines (PC-3, LNCaP, and DU145) and in PrEC normal prostate cells. Cells were grown in their normal growth media before harvested for RNA isolation and RT-PCR. A strong band was detected when the RT samples were PCR-amplified with EP4 primers after 31 cycles. This band was present in all four cell lines examined. Using the EP2 primers, only a weak band was present in all the cells after 40 cycles of amplification, suggesting a very low copy number. No RT-PCR product of the expected size was detected in any of the cell lines when EP1 or EP3 primers were used (Figure 7), even after varying the magnesium concentrations in PCR (data not shown). We conclude that the human prostate cells express EP4 and EP2 receptors and probably not EP1 or EP3.

**DISCUSSION**

The current study suggests that the mechanism by which AA increases c-fos expression and growth in PC-3 cells involves production of PGE₂ from AA, binding of PGE₂ to the EP4 and/or EP2 receptors, and subsequent activation of the PKA pathway which eventually leads to expression of growth-related genes (Figure 8). Under normal physiological conditions, AA is released from membrane phospholipids by phospholipases upon stimulation to synthesize eicosanoids (Smith, 1989). Because human cells cannot synthesize AA de novo, AA has to be obtained directly from the diet, or synthesized from linoleic acid, which is also an essential fatty acid. AA is then present in serum either as an albumin-bound acid, or as part of lipids present in lipoproteins. Habenicht et al (1990) have demonstrated that cholesteryl- AA is taken up by the cells via the LDL receptor pathway. Serum albumin-bound AA enters the cells by endocytosis (Geuskens et al, 1994; Iturradle et al, 1991; Uriel et al, 1994). After transportation into the cells, AA is incorporated into the lipid pool as part of phospholipids (Chilton et al, 1996). The mechanisms by which prostaglandins (synthesized from AA via the cyclo-oxygenase pathway) facilitate cancer transformation include generation of mutagens, stimulation of cell growth, tumour promotion and immune suppression (Marnett, 1992). The importance of the cyclo-oxygenase products in prostate cancer has also been demonstrated by a recent study (Liu et al, 1998) in which a specific COX-2 inhibitor induced apoptosis of the LNCaP human prostate cell line.

C-fos is one of the earliest induced growth response genes (Lau and Nathans, 1987; Angel and Karin, 1991). In this study, expression of c-fos measured by semi-quantitative RT-PCR increased > 1.9-fold when prostate cancer cells were treated with AA in all experiments. The increased expression of c-fos may, at least in part, account for the increased PC-3 cell growth as previously observed (Tjandrawinata et al, 1997). Our results strongly suggest that AA induces c-fos expression through the biological activity of
its product PGE₂ for two reasons. First, PGE₂ had a similar effect on c-fos expression in PC-3 cells; and second, treatment with a cyclo-oxygenase inhibitor suppressed the induction of c-fos expression by AA. To understand the signal transduction pathway(s) involved in AA-induced c-fos expression in the prostate cancer cells, specific protein kinase inhibitors were used. The results clearly indicate a role of PKA, but not PKC, in the activation of the signal transduction event. Therefore, the prostaglandin receptor(s) that mediate this event must be EP2 and/or EP4, which are linked to the PKA pathway. Consistent with the results from protein kinase inhibition experiments, RT-PCR detected EP4 as the major EP receptor expressed in human prostate cells, with a small amount of EP2 expression also detected. Expression of EP1 and EP3 was not detected. Expression of specific types of EP receptors appears to be the mechanism used by different cell types for carrying out various physiological functions of the eicosanoids.

Interestingly, the PKA inhibitor H-89 partially inhibited PGE₂ production from AA. This, however, was unlikely the cause for the complete loss of AA-induction of c-fos expression, because the PGE₂ level in presence of H-89 and AA was still much higher than in control samples. Two possibilities are proposed to explain this partial inhibition of PGE₂ synthesis. First, COX-2 is a feed-forward enzyme up-regulated by its product PGE₂ (Pilbeam et al., 1995; Tjandra and colleagues et al., 1997). Inhibition of PKA blocks the pathway by which PGE₂ exerts its cellular functions through the EP4/2 receptors in PC-3 cells. This presumably prevents further activation of cyclooxygenases, thus decreasing the amount of subsequent PGE₂ production. Second, it is possible that other stimulating factors are needed for conversion of AA into PGE₂, and the PKA inhibitor partially blocked the transmission of such signals. In our study, we also demonstrated c-fos inducibility by the phorbol ester TPA, which is a potent PKC activator and mitogen. The fact that activation of PKC in absence of the EP1 receptor induced c-fos further supported the role of EP receptors as the decisive control for the different responses to eicosanoids.

The c-fos promoter contains a serum response element (SRE), which is activated by signals through the PKC pathway (Buscher et al., 1988; Gilman, 1988). A cyclic AMP response element (CRE) is also located at 264/257 of the c-fos promoter. In mouse osteoblasts which also depend on the PKA pathway for PGE₂-induced c-fos expression, the CRE but not the SRE has been suggested to provide the inducibility by PGE₂ (Fitzgerald et al., 1999). In that study the c-fos promoter with 5′ deletions was fused to a reporter gene and the effect of exogenous PGE₂ on promoter activity studied. With the findings presented here, the CRE is also expected to confer PGE₂-inducibility in the PC-3 cells.

This report has elucidated several key steps by which certain dietary fatty acids, such as AA and its precursors, increase human prostate cell growth and cancer risk. Our results strongly suggest that PGE₂, the EP4/2 receptors, and the PKA pathway are mediators of AA induced c-fos expression in the human prostate cancer cell line PC-3.

ACKNOWLEDGEMENTS

This work was supported by the Department of Veteran’s Affairs, VAMC, San Francisco, and by NASA grant NAG-2-1086. The authors thank Dr Rajvir Dahiya for providing the LNCaP cell line. We thank Vicki Gilbertson for the comments on the manuscript and technical guidance in RT-PCR. Angela Wong provided excellent technical assistance.

REFERENCES


